IMVT Key Statistics, Chart & Performance
The current stock price of IMVT is 25.42 USD. In the past month the price increased by 15.44%. In the past year, price increased by 2.46%.
IMVT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About IMVT
Company Profile
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 362 full-time employees. The company went IPO on 2019-05-14. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The firm is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
Company Info
IMMUNOVANT INC
320 West 37Th Street
New York City NEW YORK 10018 US
CEO: Peter Salzmann
Employees: 362
Phone: 19175803099
IMMUNOVANT INC / IMVT FAQ
Can you describe the business of IMMUNOVANT INC?
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 362 full-time employees. The company went IPO on 2019-05-14. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The firm is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
What is the stock price of IMMUNOVANT INC today?
The current stock price of IMVT is 25.42 USD. The price increased by 0.28% in the last trading session.
Does IMVT stock pay dividends?
IMVT does not pay a dividend.
How is the ChartMill rating for IMMUNOVANT INC?
IMVT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for IMVT stock?
IMMUNOVANT INC (IMVT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.84).
What is the employee count for IMVT stock?
IMMUNOVANT INC (IMVT) currently has 362 employees.
What is the market capitalization of IMVT stock?
IMMUNOVANT INC (IMVT) has a market capitalization of 4.46B USD. This makes IMVT a Mid Cap stock.
IMVT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IMVT. When comparing the yearly performance of all stocks, IMVT is one of the better performing stocks in the market, outperforming 89.01% of all stocks.
IMVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMVT. IMVT has a great financial health rating, but its profitability evaluates not so good.
IMVT Financial Highlights
Over the last trailing twelve months IMVT reported a non-GAAP Earnings per Share(EPS) of -2.84. The EPS decreased by -27.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.69% | ||
| ROE | -89.39% | ||
| Debt/Equity | 0 |
IMVT Forecast & Estimates
23 analysts have analysed IMVT and the average price target is 39.49 USD. This implies a price increase of 55.34% is expected in the next year compared to the current price of 25.42.